Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia

British Journal of Biomedical Science

Volumn 61, Issue 2, 2004, Pages 103-111

  Knight, G W A ^a   McLellan, D ^b  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Chronic; Glivec; Imatinib; Leukemia; Myeloid; Philadelphia chromosome

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DAUNORUBICIN; HYDROXYUREA; IMATINIB; INTERFERON; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR;

APOPTOSIS; BIODIVERSITY; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG USE; ENZYME ACTIVITY; HUMAN; MEDICAL RESEARCH; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BINDING; REDUCTION; RELAPSE; REVIEW; RISK FACTOR; UPREGULATION;

EID: 3042747704     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2004.11732653     Document Type: Review

References (45)

1. Hoffbrand AV, Pettit JE, Moss PAH. Essential haematology (4th edn). Oxford: Blackwell Science, 2001: 180-6.
2. Edwards CRW, Bouchier IAD, Haslett C, Chilvers ER. Davidson's principles and practice of medicine (17th edn). London: Churchill Livingstone, 1996: 810-2.
3. Hoffbrand AV, Lewis SM, Tuddenham ECD. Postgraduate haematology (4th edn). Oxford: Butterworth Heinemann, 1999: 434-4.
4. McKenzie SB. Textbook of haematology (2nd edn). London: Williams and Wilkins, 1996: 313-24.
5. Goldman JM. Bailliere's Clinical Haematology International Practice and Research. Chronic myeloid Leukaemia (vol 10, number 2). London: Bailliere Tindall. 1997.
6. Sawyers CL, McLaughlin J, Goga A Havlik M, Witte O. The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 1994; 77: 121-31.
7. Barila D, Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 1998; 18(3): 280-2.
8. Pendergast AM, Muller AJ, Havlik MH, Matu Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine manner. Cell 1991; 66: 161-71.
9. Salgia R, Ewaniuk DS, Pear E et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 1997; 100: 46-57.
10. L. J Exp Med 2000; 6: 977-84.
11. Sausville EA. A Bcr/Abl Kinase antagonist for chronic myelogenous leukaemia: a promising path for progress emerges. J Nat Cancer Inst 1999; 91: 102-3.
12. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukaemic cells in chronic myeloid leukaemia. Blood 1999; 94: 2056-64.
13. Sawyers CL. Molecular studies in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors. Semin Hematol 2001; 38 (3 Supp 8): 15-21.
14. Roninson IB, Chin JE, Choi KG et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 4538.
15. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
16. Drach D, Zhao S, Drach J et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729-34.
17. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215-22.
18. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL - transformed hematopoietic cell lines. Blood 2000; 95: 3498-505.
19. le Coutre P, Tassi E, Varella-Garcia M et al. Induction of resistance to the Abelson inhibitor STI 571 in human leukaemic cells through gene amplification. Blood 2000; 95: 1758-66.
20. Mahon FX, Deininger MWN, Schultheis B et al. Selection and characterisation of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI 571: diverse mechanisms of resistance. Blood 2000; 96: 1070-9.
21. Gorre M, Mohammed M, Ellwood K et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-80.
22. Krauss G. Biochemistry of signal transduction and regulation. New York: Wiley, 1999; : 298-324.
23. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Beininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611-4.
24. Gambacorti-Passerini, Piazza R, D'Incalci. Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood 2003; 102: 1933-4.
25. Theising JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukaemic agents against Bcr-Abl-positive cells. Blood 2000; 96: 3195-9.
26. Mayer IA, Verma A, Grumbach IM et al. The p38 pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL expressing cells. J Biol Chem 2001; 276: 28570-7.
27. Wagner JE, Zahurak M, Piantadosi S et al. Bone marrow transplantation of chronic myelogenous leukaemia in chronic phase: evaluation of risks and benefits. J Clin Oncol 1992; 10: 779-89.
28. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of Busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukaemia: Developed for the American Society of Hematology. Blood 1999; 94: 1517-36.
29. Bruchova H, Borovanova T, Klamova H, Brdicka R. Gene expression profiling in chronic myeloid leukaemia patients treated with hydroxyurea. Leuk Lymphoma 2002; 43: 1289-95.
30. Marin D, Marktel S, Szydlo R et al. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet 2003; 362: 617-9.
31. Kantarjian H, O'Brien S, Cortes J et al. Analysis of the impact on imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome positive chronic myelogenous leukaemia treated with interferon a regimens for early chronic phase. Cancer 2003; 98: 1430-7.
32. Druker BJ. The IRIS study - International Randomisation of Interferon + Ara-C vs STI571 (Imatinib/Glivec/Gleevec) in chronic myeloid leukaemia. Orlando: American Society for Clinical Oncology, 2002.
33. O'Brien SG. Rule SAJ, on behalf of the BCSH (28 Aug 2002). Position paper on imatinib mesylate in chronic myeloid leukaemia. www.bcshguidelines.org.
34. National Institute for Clinical Excellence. Final Appraisal Determination - Imatinib for chronic myeloid leukaemia. August 2003.
35. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.
36. Spencer A, O'Brien SG, Goldman JM. Options for therapy in chronic myeloid leukaemia. Br J Haematol 1995; 91: 2-7.
37. Sawyers CL, Hochhaus A, Feldmann JM, Goldman JM, Miller CB, Ottmann OG. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-9.
38. Huntly B, Reid A, Bench A et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic factor in chronic myeloid leukaemia. Blood 2001; 98: 1732-8.
39. Huntly BJ, Guilhot F, Reid AG et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102: 2205-12.
40. Schittenhelm M, Aichele O, Krober SM, Brummendorf T, Kanz L, Denzlinger C. Complete remission of third recurrence of acute myeloid leukaemia after treatment with imatinib (STI 571). Leuk Lymphoma 2003; 44: 1251-3.
41. Attoub S, Rivat C, Rodriguez S et al. The c-Kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 2002; 62: 4879-83.
42. Demetri CD, Von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002; 347: 472-80.
43. Verweij J, van Oosterom A, Blay YJ, Judson I, Rtodenhuis S, van der Graaf W. Imatinib mesylate (STI 571, Glivec, Gleevec™) is an active agent for gastrointestinal stromal rumours, but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur J Cancer 2003; 39: 2006-11.
44. Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-4.
45. Moses AV, Jarvis MA, Raggo C et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-Kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002; 776: 8383-99.